Abstract: Disclosed in the present invention is a crystalline form of fluvatinib or fluvatinib methanesulfonate, and a preparation method therefor. The crystalline form I of the fluvatinib has characteristic diffraction peaks as shown in FIG. 1. The crystalline form of the fluvatinib methanesulfonate may take multiple forms, including seven crystalline forms, forms I-VII, wherein crystalline form III has characteristic diffraction peaks as shown in FIG. 9. Said crystalline forms are suited to manufacturing processes for fluvatinib methanesulfonate formulations.

Abstract: The present disclosure relates to a GLP-1R agonist compound and use thereof, and specifically provides a compound represented by Formula I, or an isotope-labelled compound, a stereoisomer, or a pharmaceutically acceptable salt thereof, and use thereof as a medicament. The compound exhibits excellent agonistic effects and pharmacodynamic properties on GLP-1R and, as a modulator, is useful for manufacturing a medicament for the treatment, amelioration, or prevention of metabolic diseases and related diseases, thus having broad application prospects.

Abstract: Disclosed in the present invention is a crystalline form of fluvatinib or fluvatinib methanesulfonate, and a preparation method therefor. The crystalline form I of the fluvatinib has characteristic diffraction peaks as shown in FIG. 1. The crystalline form of the fluvatinib methanesulfonate may take multiple forms, including seven crystalline forms, forms I-VII, wherein crystalline form III has characteristic diffraction peaks as shown in FIG. 9. Said crystalline forms are suited to manufacturing processes for fluvatinib methanesulfonate formulations.

Abstract: Provided is an application of the combination of a quinoline derivative and an immunomodulator in preparation of antitumor drugs.

Abstract: A quinoline derivative compound shown in formula (II), a pharmaceutically acceptable salt thereof, and an application of the same in preparing a drug for treating a disease related to a tyrosine kinase inhibitor.

Abstract: An organic amine ester derivative drug of 2-(?-hydroxypentyl)benzoic acid and a preparation method thereof and an use thereof are disclosed. The present disclosure particularly relates to a compound having the general formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable formulation prepared from the compound or the pharmaceutically acceptable salt thereof. The compound having the general formula I or the pharmaceutically acceptable salt thereof has in vitro a good solubility and a low hygroscopicity, and has in vivo a bioavailability and a brain aggregation concentration that are significantly greater than those of the original medicine butyphthalide and/or an improving drug efficacy. The use of the compound in the preparation of a drug for preventing and/or treating heart and cerebral ischemic diseases, a drug for preventing and/or treating heart and cerebral artery occlusion diseases, an anti-parkinsonian drug and an anti-senile-dementia drug is also disclosed.

Abstract: A compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable formulation prepared using the compound and the salt. The compound represented by formula (I) or the pharmaceutically acceptable salt exhibits significantly higher buildup and concentration in the lungs compared to other tissues, a longer dwell time in the lungs, and/or elevated pharmaceutical efficacy.

Abstract: An in situ phase change gel sustained-release preparation for a small molecule drug and a preparation method thereof. The in situ phase change gel sustained-release preparation comprises a small molecule drug comprising an active pharmaceutical ingredient, a phospholipid, Span, and an ethanol solution. The in situ phase change gel sustained-release preparation has a high concentration of phospholipids combined with Span, and is thus able to reduce the immediate-release of the small molecule drug and extend the release time, and is suitable for various administration routes, such as subcutaneous injection and external administration.

Abstract: Provided is a nRGD polypeptide formed by connecting alanine-alanine-asparagine (AAN) and a polypeptide containing arginine-glycine-aspartic acid (RGD), wherein the nRGD polypeptide can target tumor vessels, tumor cells and tumor-associated macrophages, and mediate the targeted delivery of tumors.

Abstract: A compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable formulation prepared using the compound and the salt. The compound represented by formula (I) or the pharmaceutically acceptable salt exhibits significantly higher buildup and concentration in the lungs compared to other tissues, a longer dwell time in the lungs, and/or elevated pharmaceutical efficacy.

Abstract: Provided is a nRGD polypeptide formed by connecting alanine-alanine-asparagine (AAN) and a polypeptide containing arginine-glycine-aspartic acid (RGD), wherein the nRGD polypeptide can target tumour vessels, tumour cells and tumour-associated macrophages, and mediate the targeted delivery of tumours.